Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 5;10:31. doi: 10.1186/s13148-018-0466-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Kaplan-Meier overall survival analysis based on CIMP subgroups in BCP-ALL. Overall survival analysis in a 601 diagnostic BCP-ALL samples CIMP classified at diagnosis. Follow-up time (months) from diagnosis to last follow-up. b–e One hundred and thirty-seven relapsed BCP-ALL samples CIMP classified at diagnosis and stratified for c initial risk-group at primary diagnosis (SR/IR and HR), based on age at diagnosis, immunophenotype, cytogenetic aberrations, WBC, and CNS involvement. d Hematopoietic stem cell transplantation after relapse (yes/no). e IntReALL (International Study for Treatment of Childhood Relapse ALL) risk class (SR/HR) at relapse, based on site of relapse and time from diagnosis to relapse. Follow–up time (months) from relapse to last follow up (b–e)